MaveriX is a globally-orientated biotechnology company focused on the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies.
Our technology approach leverages unexploited insights into cancer and immune cell metabolism within the tumor microenvironment which are common to all cancers.
Our novel platform is designed to selectively deliver the tumor cell killing benefits of chemotherapy while generating a robust immune response to attack a wide range of cancers.
Our experienced team is developing a proprietary pipeline of drug candidates with the goal of bringing new and improved treatments to patients suffering from cancer.
PPF and SOTIO invest $6.5 million in MaveriX Oncology and its lead program MVX-5005